147 related articles for article (PubMed ID: 2573682)
1. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.
Mitchell JB; Russo A; Cook JA; Straus KL; Glatstein E
Int J Radiat Biol; 1989 Nov; 56(5):827-36. PubMed ID: 2573682
[TBL] [Abstract][Full Text] [Related]
2. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
[TBL] [Abstract][Full Text] [Related]
3. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
[TBL] [Abstract][Full Text] [Related]
4. Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.
Epstein AH; Lebovics RS; Goffman T; Teague D; Fuetsch ES; Glatstein E; Okunieff P; Cook JA
J Natl Cancer Inst; 1994 Dec; 86(23):1775-80. PubMed ID: 7966416
[TBL] [Abstract][Full Text] [Related]
5. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy.
Mitchell JB; Russo A; Kinsella TJ; Glatstein E
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1513-8. PubMed ID: 3531118
[TBL] [Abstract][Full Text] [Related]
6. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo.
Rodriguez R; Ritter MA; Fowler JF; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):105-13. PubMed ID: 8175417
[TBL] [Abstract][Full Text] [Related]
8. The clinical rationale for S-phase radiosensitization in human tumors.
McGinn CJ; Kinsella TJ
Curr Probl Cancer; 1993; 17(5):273-321. PubMed ID: 8281809
[TBL] [Abstract][Full Text] [Related]
9. Tumour radiosensitization with the halogenated pyrimidines 5'-bromo- and 5'-iododeoxyuridine.
Epstein AH; Cook JA; Goffman T; Glatstein E
BJR Suppl; 1992; 24():209-14. PubMed ID: 1290703
[No Abstract] [Full Text] [Related]
10. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure.
Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1393-8. PubMed ID: 2370189
[TBL] [Abstract][Full Text] [Related]
11. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells.
Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
Radiat Res; 1990 Aug; 123(2):192-8. PubMed ID: 2389005
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs.
Kinsella TJ; Dobson PP; Mitchell JB; Fornace AJ
Int J Radiat Oncol Biol Phys; 1987 May; 13(5):733-9. PubMed ID: 3570896
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
[TBL] [Abstract][Full Text] [Related]
14. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
15. Halogenated pyrimidines as radiosensitizers for high-LET radiation.
Atcher RW; Russo A; DeGraff WG; Moore M; Grdina DJ; Mitchell JB
Radiat Res; 1989 Feb; 117(2):351-5. PubMed ID: 2922478
[TBL] [Abstract][Full Text] [Related]
16. Iododeoxyuridine incorporation and radiosensitization in three human tumor cell lines.
Uhl V; Phillips TL; Ross GY; Bodell WJ; Rasmussen J
Int J Radiat Oncol Biol Phys; 1992; 22(3):489-94. PubMed ID: 1735685
[TBL] [Abstract][Full Text] [Related]
17. Modification of radiotherapy by radiosensitizers and cancer chemotherapy agents. I. Radiosensitizers.
Coleman CN
Semin Oncol; 1989 Jun; 16(3):169-75. PubMed ID: 2658080
[No Abstract] [Full Text] [Related]
18. Photon activation therapy.
Fairchild RG; Bond VP
Strahlentherapie; 1984 Dec; 160(12):758-63. PubMed ID: 6515666
[TBL] [Abstract][Full Text] [Related]
19. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
[TBL] [Abstract][Full Text] [Related]
20. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
